PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.73%
R&D reduction while AXSM shows 10.62% growth. Joel Greenblatt would examine competitive risk.
522.30%
G&A change of 522.30% while AXSM maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
3069944.64%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
230.56%
Operating expenses growth above 1.5x AXSM's 6.62%. Michael Burry would check for inefficiency.
230.56%
Total costs growth above 1.5x AXSM's 8.31%. Michael Burry would check for inefficiency.
243.75%
Interest expense growth above 1.5x AXSM's 24.56%. Michael Burry would check for over-leverage.
418.75%
D&A growth while AXSM reduces D&A. John Neff would investigate differences.
-202.01%
EBITDA decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-230.56%
Operating income decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-494.03%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-176.90%
Pre-tax income decline while AXSM shows 17.64% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-100.18%
Tax expense reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine advantage.
-176.90%
Net income decline while AXSM shows 19.26% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
89.62%
EPS growth exceeding 1.5x AXSM's 20.49%. David Dodd would verify competitive advantages.
89.62%
Diluted EPS growth exceeding 1.5x AXSM's 20.49%. David Dodd would verify competitive advantages.
2567.99%
Share count reduction below 50% of AXSM's 1.17%. Michael Burry would check for concerns.
2567.99%
Diluted share reduction below 50% of AXSM's 1.17%. Michael Burry would check for concerns.